Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Finished Goods (2017 - 2025)

Historic Finished Goods for Ultragenyx Pharmaceutical (RARE) over the last 9 years, with Q3 2025 value amounting to $23.0 million.

  • Ultragenyx Pharmaceutical's Finished Goods fell 17.79% to $23.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.0 million, marking a year-over-year decrease of 17.79%. This contributed to the annual value of $23.0 million for FY2024, which is 5248.18% up from last year.
  • Ultragenyx Pharmaceutical's Finished Goods amounted to $23.0 million in Q3 2025, which was down 17.79% from $26.7 million recorded in Q2 2025.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Finished Goods peaked at $26.7 million during Q2 2025, and registered a low of $4.9 million during Q2 2022.
  • Its 5-year average for Finished Goods is $12.9 million, with a median of $11.5 million in 2023.
  • As far as peak fluctuations go, Ultragenyx Pharmaceutical's Finished Goods plummeted by 1308.21% in 2022, and later soared by 10798.75% in 2023.
  • Ultragenyx Pharmaceutical's Finished Goods (Quarter) stood at $5.7 million in 2021, then surged by 62.04% to $9.3 million in 2022, then soared by 62.82% to $15.1 million in 2023, then surged by 52.48% to $23.0 million in 2024, then dropped by 0.12% to $23.0 million in 2025.
  • Its last three reported values are $23.0 million in Q3 2025, $26.7 million for Q2 2025, and $23.1 million during Q1 2025.